News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Luminex (LMNX) Release: ARIES System And Flu A/B & RSV Assay Evaluated By Erasmus MC In New Publication



11/17/2016 9:09:52 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the internationally renowned Department of Viroscience at Erasmus Medical Center in Rotterdam, The Netherlands, has evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for clinical testing in a recently published study. Erasmus MC is a consultation center for the World Health Organization on viral infections, as well as serving as the National Reference Center for Influenza and Emerging Infections in The Netherlands.

The ARIES(R) Flu A/B & RSV Assay is a rapid, accurate method for the detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) from nasopharyngeal swab (NPS) specimens using the ARIES(R) System.

In the study, the ARIES® platform and Flu A/B & RSV Assay showed a high clinical specificity and sensitivity, comparable to laboratory developed RT-PCR assays, and better than those of established assays such as immunochromatographic tests and direct immunofluorescence assays. Ease of use was found to be comparable to other rapid molecular test platforms. The ARIES® platform is unique in that it can also run in-house developed real-time assays with generic ARIES® cassettes.

"We are proud that after thorough evaluation, ARIES has been found to be effective and easy to use by one of the world's leading medical centers for clinical virology," said Thomas Pracht, Managing Director, EMEIA, at Luminex Corporation. "The Erasmus study demonstrates the quality and performance of the ARIES® platform and the value of the system for molecular diagnostic labs that want to perform 'out of sync' MDx testing in other words, outside of office hours testing or stat testing during office hours in between runs. The study also underlines the importance of 'point of impact' tests, where results have an immediate impact on patient care and clinical decision making, even outside normal office hours." 

Read the complete study, "Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and respiratory syncytial viruses," published in the Journal of Clinical Virology, December 2016, Volume 85, Pages 6570.

About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity, and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at luminexcorp.com. 

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the development and testing progress of our pipeline products, and the regulatory approvals thereof. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts


Luminex Investor Contact

Luminex Media Contact

Harriss Currie

Christine Valle

Sr. Vice President of Finance and CFO

Sr. Manager, Global Marketing

512.219.8020

512.219.8020

hcurrie@luminexcorp.com

cvalle@luminexcorp.com

 

Luminex logo. (PRNewsFoto/LUMINEX CORP.)

Photo - http://photos.prnewswire.com/prnh/20161116/440243 
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aries-system-and-flu-ab--rsv-assay-evaluated-by-erasmus-mc-in-new-publication-300364612.html

SOURCE Luminex Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES